eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
1/2014
vol. 39
 
Share:
Send email
Share:
abstract:

CD4+CD25+ regulatory T cells as a therapeutic target in rheumatoid arthritis

Qing Yu
,
Man Xu
,
Fang Yu
,
Yong Jin

(Centr Eur J Immunol 2014; 39 (1): 100-103
DOI: https://doi.org/10.5114/ceji.2014.42133
Online publish date: 2014/04/22
View full text Get citation
 
PlumX metrics:
CD4+CD25+ T cells are regulatory T cells (CD4+CD25+ Tregs), which can strengthen immune tolerance. They play a critical role in controlling the development of autoimmune diseases in animals and humans. Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the peripheral joints and eventually leads to joint destruction. Although the pathogenesis of RA remains unknown, it is supposed to be affected by autoreactive T cells and antibodies. At the same time, to make the CD4+CD25+ T cells active and to increase the number of the cells are responsible in the therapy of RA in recent studies. Now, many techniques about expansion of Tregs in vitro have been established to overcome the problem of their limited numbers in vivo. It is important to carry out a study of induction or amplification of Tregs in vitro. Here, we review our current understanding of CD4+CD25+ T cells in RA and the targeting of these cells in RA therapy.
keywords:

CD4+CD25+ regulatory T cells, autoimmune diseases, immune tolerance, rheumatoid arthritis
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.